Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Relypsa reports results from Phase 1 in vivo studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa and 12 drugs administered either at the same time or...
-
REDWOOD CITY, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 15, 2016, the compensation committee of the...
-
REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 4, 2016, the compensation committee of the...
-
Veltassa is the first FDA-approved medicine for hyperkalemia in more than 50 years Veltassa will be distributed to patients via two nationally-recognized specialty pharmaciesHospitals will receive...
-
REDWOOD CITY, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 15, 2015, the compensation committee of the...
-
REDWOOD CITY, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 1, 2015, the compensation committee of the...
-
REDWOOD CITY, Calif., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 26th...
-
REDWOOD CITY, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on November 16, 2015, the compensation committee of the...
-
Veltassa significantly reduced and maintained control of blood potassium levels in OPAL-HK pre-specified sub-group analysis of patients age 65 and older with chronic kidney disease (CKD) and...
-
REDWOOD CITY, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on November 2, 2015, the compensation committee of the...